Span Divergent Quarterly Results
Span Divergent quarterly results. In Sept 2025, Span Divergent (SDL) reported revenue ₹8 Cr and net profit ₹0 Cr — revenue +166.7% YoY. For annual financials, live price and key ratios, visit Span Divergent share price screener.
SDL Quarterly Results — Revenue, Profit & EPS Highlights
Span Divergent latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore SDL price movement history to track price trends across different timeframes.
- Revenue of ₹8 Cr in Sept 2025 (+700.0% vs Mar 2025, +166.7% vs Sept 2024)
- Operating Margin of -1.0% in Sept 2025 (+197.0pp vs Mar 2025)
- Earnings Per Share of ₹-0.34 in Sept 2025 (+81.8% vs Mar 2025)
Span Divergent Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SDL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 8 | 1 | 2 | 3 | 4 | 700.0% | 166.7% |
| Net Profit (₹ Cr) | 0 | -1 | 0 | 0 | 1 | - | - |
| EBITDA (₹ Cr) | 0 | -1 | 0 | 0 | 1 | - | - |
| EPS (₹) | -0.34 | -1.87 | -0.31 | 0.09 | 1.62 | - | - |
| Operating Margin (%) | -1.0% | -198.0% | -81.0% | 5.0% | -2.0% | - | - |
SDL Share Price Trend — 1-Year Movement Across Quarterly Results
Span Divergent 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View SDL price range for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SDL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Span Divergent latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1900.0 | 16,617 | 1,995 | +10.6% | - | 12.0% | 228.9 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11178.0 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4611.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 400.6 |
|
Apollo Hospitals
Sept 2026 |
₹126,832.45 Cr | 8738.0 | 7,673 | 660 | +15.2% | - | 8.6% | 199.4 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2306.0 | 2,219 | 436 | +21.7% | - | 19.6% | 282.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores